Yes, they can, says Professor Dominique Belpomme and team, writing in the International Journal of Molecular Sciences. They believe electromagnetic hypersensitivity (EHS) is a real and verifiable condition and should be acknowledged as such.
The authors point out that there is adequate clinical evidence to establish that EHS is ‘a distinct neuropathological disorder’ and they want to see it classified in the WHO International Classification of Diseases.
By clinical research, they mean biological markers that can be objectively observed and measured in patients. ‘These have now been shown to primarily involve low-grade inflammation, oxidative/nitrosative stress and, consequently, blood-brain barrier opening,’ they say. Clinical evidence is commonly used to diagnose diseases like cancer, diabetes type 2, cardiac problems and Alzheimer’s Disease, for example.
Belpomme points out that, while clinical research describes a condition, it doesn’t prove what causes it. Take cancer, for example. Laboratory tests define it, whereas it’s the population studies that show it’s linked with smoking, asbestos and so on.
In the case of EHS, early research looked for a link between exposure and symptoms to determine whether the one caused the other. It wasn’t always successful and that led some critics to conclude that EHS isn’t real.
Belpomme points out the problems with that sort of logic. ‘EHS first should have been objectively defined as a distinct pathological disorder thanks to the use of critical and rigorous methods of clinical research ….rather than attempting to search for EMF-related causality before EHS was objectively defined.’
Now that the markers for EHS have been clinically defined, could this condition be caused by electromagnetic exposures?
Belpomme suggests that they could. He hypothesizes that ‘EHS and MCS [Multiple chemical Sensitivity] are pathological disorders of the brain, as has been suggested by imaging techniques, and that under the general term “environmental stressors”, environmental EMFs and/or chemicals may be causally involved in their pathogenesis, as suggested by in vitro experimental and clinical data.’
Nevertheless, the identification of clinical markers means that EHS and MCS can be both diagnosed and treated—and that’s good news for sufferers.
Belpomme D, Carlo GL, Irigaray P, et al. The Critical Importance of Molecular Biomarkers and Imaging in the Study of Electrohypersensitivity. A Scientific Consensus International Report. Int J Mol Sci. 2021;22(14):7321. Published 2021 Jul 7. doi:10.3390/ijms22147321
Don’t forget, you still have a chance to forward us questions that you would like answered by Professor Dariusz Leszczynski, a world-recognised authority on electromagnetic radiation.
If you have a question for Professor Leszczynski, please send it to EMR Australia by reply email. We look forward to hearing from you.
Source: EMF Australia
What you can do
- Measure your exposure in your home or office.
- Learn more and reduce the exposure in your home with our online course.
- Book an EMF Consultation